Skip to main content
main-content

Insulin pumps

09-23-2022 | EASD 2022 | Conference coverage | News

Bolus timing requires more attention in people using advanced technologies for type 1 diabetes

Delayed prandial insulin boluses are common in people using advanced technologies for the management of type 1 diabetes and are associated with adverse glycemic outcomes, suggest real-world study results.

Girl with CGM

09-21-2022 | EASD 2022 | Conference coverage | News

Skin reactions rarely lead to diabetes device discontinuation

Skin reactions to glucose monitors and insulin pumps occur in more than a quarter of users but only occasionally result in device discontinuation, research shows.

09-20-2022 | EASD 2022 | Conference coverage | News

Insulin pump delivery may reduce fatty liver risk in type 1 diabetes

Using an insulin pump rather than multiple daily injections may help protect people with type 1 diabetes from developing fatty liver disease, report researchers.

06-08-2022 | ADA 2022 | Conference coverage | News

OpenAPS closed-loop algorithm improves glucose control in formal trial

Closed-loop insulin delivery with the open-source OpenAPS algorithm results in significantly better glucose control than sensor-augmented pump delivery in children and adults in the randomized CREATE trial.

03-11-2022 | Insulin pumps | News

Insulin pump infusion set failures most common in youngest users

Insulin pump infusion set failures that result in prolonged hyperglycemia occur an average of four times per year per user and are more common in children and adolescents than adults, US study findings indicate.

08-20-2021 | Ultra-rapid lispro | News

FDA approves ultra-rapid lispro for use in pumps

Click through to read more on this announcement

05-13-2021 | Insulin pumps | News

Similar glycemic control with insulin pumps vs MDI in children with type 1 diabetes

Use of an insulin pump is not associated with better glycemic control than multiple daily injections among children and adolescents with type 1 diabetes, indicate real-world study results.

03-31-2021 | Older adults | News

Glargine-300 might be preferable for older people with type 2 diabetes

Analysis of older participants in the BRIGHT trial suggests that this subgroup may do slightly better with insulin glargine-300 than with degludec.

Related topics

Superior

Related